More color on Abbott's Q1 results

Overall operational sales for Q1 grew 0.5% for Abbott Laboratories (ABT) to ~$5.2B. Diagnostics and Medical Devices grew 5.1% and 0.3%, respectively, while Nutrition fell 1.7% and Pharmaceuticals fell 0.7%.

International operations continue to deliver higher growth rates than domestic ops.

Ex-U.S. business delivered ~72% of global sales.

In the Nutrition segment, Adult International grew 12.4% versus growth in the U.S. of 5.2%. Pediatric fell in both markets.

Diagnostics grew in all segments and markets led by Molecular's 12.6% and POC's 10% increase internationally.

Pharmaceutical sales in key emerging markets (led by BRIC) were almost flat with a slight 0.2% gain.

International Device sales grew 4.7%.

Management confirms its 2014 EPS guidance range of $2.16 - $2.26 ex items.

GAAP EPS range for the fiscal year is $1.13 - $1.23.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs